DiaMedica Therapeutics Inc. Research And Development Expense

• DiaMedica Therapeutics Inc. showed an increase of +29.2% in Research And Development Expense from 2024 to 2025.
• This data is from DiaMedica Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), DiaMedica Therapeutics Inc.'s Research And Development Expense has grown by 667.7%.
• Historical annual values: Fiscal year 2025: $24.61 million | Fiscal year 2024: $19.06 million | Fiscal year 2023: $13.11 million | Fiscal year 2022: $7.84 million | Fiscal year 2021: $8.77 million | Fiscal year 2020: $8.21 million | Fiscal year 2019: $7.90 million | Fiscal year 2018: $4.52 million | Fiscal year 2017: $3.21 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026